![Leslie Tari](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Leslie Tari
Directeur Technique/Scientifique/R&D chez CIDARA THERAPEUTICS, INC.
Fortune : 235 666 $ au 31/05/2024
Postes actifs de Leslie Tari
Sociétés | Poste | Début | Fin |
---|---|---|---|
CIDARA THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 01/03/2019 | - |
Corporate Officer/Principal | 01/07/2014 | 01/03/2019 |
Historique de carrière de Leslie Tari
Anciens postes connus de Leslie Tari
Sociétés | Poste | Début | Fin |
---|---|---|---|
Trius Therapeutics, Inc.
![]() Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | Corporate Officer/Principal | 01/03/2007 | 01/03/2014 |
ActiveSight
![]() ActiveSight Medical DistributorsDistribution Services ActiveSight designed and developed protein portfolio drugs. The company was founded by Ronald V. Swanson and Duncan McRee and was headquartered in San Diego, CA. | Fondateur | 01/01/2003 | 01/01/2007 |
Corporate Officer/Principal | 01/01/2003 | 01/01/2007 | |
Syrrx, Inc.
![]() Syrrx, Inc. Pharmaceuticals: MajorHealth Technology Syrrx, Inc. used to develops drugs. Its focus was on creating novel therapies for cancer, metabolic diseases and inflammation. The company was the technology leader in the field of structural proteomics, the process of generating protein structures from genetic information. It was headquartered in San Diego, CA | Corporate Officer/Principal | 01/01/2001 | 01/01/2003 |
Formation de Leslie Tari
University of Manitoba | Doctorate Degree |
Statistiques
Internationale
Etats-Unis | 5 |
Canada | 2 |
Opérationnelle
Corporate Officer/Principal | 4 |
Chief Tech/Sci/R&D Officer | 1 |
Doctorate Degree | 1 |
Sectorielle
Health Technology | 4 |
Consumer Services | 2 |
Distribution Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
CIDARA THERAPEUTICS, INC. | Health Technology |
Entreprise privées | 3 |
---|---|
ActiveSight
![]() ActiveSight Medical DistributorsDistribution Services ActiveSight designed and developed protein portfolio drugs. The company was founded by Ronald V. Swanson and Duncan McRee and was headquartered in San Diego, CA. | Distribution Services |
Syrrx, Inc.
![]() Syrrx, Inc. Pharmaceuticals: MajorHealth Technology Syrrx, Inc. used to develops drugs. Its focus was on creating novel therapies for cancer, metabolic diseases and inflammation. The company was the technology leader in the field of structural proteomics, the process of generating protein structures from genetic information. It was headquartered in San Diego, CA | Health Technology |
Trius Therapeutics, Inc.
![]() Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | Health Technology |
- Bourse
- Insiders
- Leslie Tari
- Expérience